Cytobank associates with FDA to enhance Immunotherapy Development
Results to be presented at The Molecular Medicine Tri-Conference in San Francisco
Cytobank and the U.S Food and Drug Administration collaborate to develop machine learning-based methods for characterizing the morphology of multipotent mesenchymal stromal cells (MSCs). These methods could be used in cellular manufacturing processes to characterize cellular preparations with desired immunotherapeutic properties.
The collaboration exhibits the ability and expertise of Cytobank’s cloud-based informatics platform to identify specific subpopulations from a mixed population of MSCs.
David Craford, President and Chief Executive Officer of Cytobank claimed “Machine learning-based approaches like these we are developing with the FDA have been used by our research customers for years to build their understanding of the immune system at the single cell level. We are excited by the potential to apply our proven research approaches in more development related applications, including cell characterization.”
Human MSCs are utilized for multiple clinical applications in regenerative medicine including heart, bone, and neurological conditions. There are approximately 650 clinical trials underway globally. According to Grand View Research the global stem cell market revenue is currently estimated at USD $7B and expected to reach $15B by 2025.